fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

Phase III trial of SB 393 plus Vidaza in acute myeloid leukaemia discontinued.- Helsinn + MEI Pharma

Written by | 3 Jul 2020 | Pharmacy

Helsinn and MEI Pharma have discontinued a Phase III trial of SB 393 (pracinostat) in combination with Vidaza (azacitidine) in patients with acute myeloid leukaemia (AML) who are unsuitable for standard intensive chemotherapy. This comes after an interim futility analysis by the independent data monitoring committee indicated that it was unlikely to meet its primary endpoint of overall survival.

The study has enrolled an estimated 500 adults with newly-diagnosed AML who are unfit to receive intensive remission induction chemotherapy due to being 75 years or older or because they have comorbidities. Patients received either pracinostat or placebo, both with azacitidine therapy. Aside from the primary OS endpoint, the study was assessing morphologic complete remission, duration of complete remission and event-free survival as secondary goals. Helsinn and MEI Pharma report that the decision was not due to any safety concerns.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.